Key Highlights
- 8.85% is the indicated pre-market decline for BioNexus Gene Lab Corp (NASDAQ:BGLC) on November 17, 2026, taking the price to USD 0.7474 from a calculated prior close of USD 0.8199, a calculated move of -USD 0.0725.
- 1.81 million is the calculated market Capitalization in USD, using 2.42 million common shares at June 30, 2026 and the indicated price of USD 0.7474, which places the company deep in nano-cap territory.
- 67.3% is the decline in trailing twelve-month Revenue to USD 3.13 million, while the trailing net loss was USD 2.58 million, or USD 1.19 per share, against 2025 revenue of USD 7.42 million.
- 3 financing structures stand out: a USD 100 million shelf registration with a USD 20 million at-the-market program on November 10, 2025, and a USD 500 million Equity Facility announced December 2, 2025.
What Moved BioNexus Gene Lab Corp (NASDAQ:BGLC) in Pre-Market Trading on November 17, 2026 (-USD 0.0725, -8.85%)
The indicated pre-market price for BioNexus Gene Lab Corp (NASDAQ:BGLC) is USD 0.7474 on November 17, 2026, a pre-market move of -8.85%. The calculated prior close is USD 0.8199 (USD 0.7474 divided by 0.9115), and the calculated USD move is -USD 0.0725. Using 2.42 million common shares at June 30, 2026, the calculated market capitalization is about USD 1.81 million. The stock was quoted near USD 1.44 in mid-September 2026, so the indicated price reflects a sizeable decline since then. Pre-market Volume was not found.
The Rationale: No Single Catalyst Identified Beyond VitaGuard and Financing Themes for BioNexus Gene Lab Corp (NASDAQ:BGLC)
No catalyst for the November 17, 2026 decline was identified in published coverage. As general context, a low-priced nano-cap with a small float can move several percentage points on modest order flow, and overhang from equity facilities can weigh on sentiment. Company news in the past year included a definitive agreement with Fidelion Diagnostics on November 12, 2025, an exclusive Southeast Asia license for the VitaGuard minimal residual disease platform on December 1, 2025, a 15% equity stake in Fidelion completed December 3, 2025, and a VitaGuard rollout update on July 28, 2026.
Valuation, Liquidity and Risks for BioNexus Gene Lab Corp (NASDAQ:BGLC)
BioNexus sells chemical raw materials for industrial, medical and electronics manufacturing, mainly in Malaysia, Indonesia and Vietnam, and also runs a genomic screening segment. It was founded in 2017 and has 19 employees. At June 30, 2026, cash was USD 1.23 million versus USD 1.34 million at March 31, 2026, total Debt was USD 0.32 million, total Assets were USD 8.73 million and shareholders' equity was USD 7.78 million. The calculated Market Value sits far below book equity, yet equity facilities and the at-the-market program create dilution risk, and the nano-cap profile magnifies volatility.
Where Things Stand
BioNexus Gene Lab Corp (NASDAQ:BGLC) is indicated down 8.85% in pre-market trading on November 17, 2026, at USD 0.7474, a calculated decline of USD 0.0725 from a prior close of USD 0.8199. No specific catalyst was identified in published coverage. The calculated market capitalization is about USD 1.81 million on 2.42 million shares, trailing revenue fell 67.3% to USD 3.13 million, and cash was USD 1.23 million at June 30, 2026. Dilution risk from the USD 500 million equity facility and the USD 20 million at-the-market program remains central, and pre-market moves in thinly traded nano-caps can reverse quickly. This article is informational and is not Investment advice.






Please wait processing your request...